![]() |
|
|
Vol. 288, Issue 2, 834-837, February 1999
Molecular Neurocardiology Laboratory, Baker Medical Research Institute, Prahan, Victoria, Australia
| |
Abstract |
|---|
|
|
|---|
The benzofuran antiarrhythmic drug, amiodarone, exhibits a wide range
of pharmacological properties. Recent in vivo biochemical studies
suggest that amiodarone may exert an antiadrenergic action in the
heart, which resembles the effects of reserpine. To investigate the
cellular basis for this apparent presynaptic, sympatholytic action we
used Chinese hamster ovary (CHO) cells expressing the type 2 vesicular
monoamine transporter (VMAT2) as a synaptic vesicular model. Amiodarone
inhibited the uptake of [3H]norepinephrine in
VMAT2-transfected CHO cells in a concentration-dependent manner, with a
log EC50 of 6.44 ± 0.32. To further identify
the site at which amiodarone suppressed vesicular monoamine transport, we examined the ability of amiodarone to displace
[3H]reserpine from its binding site in membrane fractions
prepared from CHO cells expressing VMAT2. [3H]Reserpine
binding was inhibited in a concentration-dependent manner by
amiodarone, with an
log EC50 of 6.76 ± 0.03, reaching 84 ± 5% inhibition of reserpine binding at 10 µM. A
pH-dependent mechanism for this action of amiodarone was excluded in
studies using the pH-sensitive fluorescent indicator 2',7'-bis
(carboxyethyl)-5,6-carboxyfluorescein (BCECF). These data indicate that
amiodarone inhibits the uptake of monoamine into the axoplasmic storage
vesicle by inhibiting VMAT. Furthermore, amiodarone competes
specifically with reserpine for binding to VMAT. These findings suggest
a novel presynaptic site of action for amiodarone.
| |
Introduction |
|---|
|
|
|---|
Amiodarone,
a benzofuran derivative, is a commonly used antiarrhythmic agent
that was initially developed as an antianginal agent. This complex drug
has been demonstrated to block K+,
Na+, and Ca++ channels, in
addition to having an incompletely characterized antisympathetic
action. The antiadrenergic actions of amiodarone are complex. In
isolated tissues, amiodarone has been characterized as a noncompetitive
beta adrenoceptor antagonist (Polster and Broekhuysen,
1976
), whereas in intact animals, amiodarone has been shown to cause a
bradycardia that is apparently independent of actions on
beta adrenoceptors (Charlier, 1970
). More recently, Du
et al. (1995)
, demonstrated a "reserpine-like" effect of amiodarone characterized by an increase in the overflow of dihydroxyphenylglycol (DHPG), the major intraneuronal metabolite of norepinephrine (NE), from the rat heart. This action was accompanied by a reduction in the
cardiac NE tissue content, and in conjunction, an attenuation of the
release of NE in response to electrical stimulation of the cardiac
sympathetic nerves.
Reserpine, a Rauwolfia alkaloid, prevents the transport of amines into
chromaffin granules and synaptic storage vesicles (Darchen et al.,
1989
; Schuldiner et al., 1995
) by binding with high affinity to the
vesicular monoamine transporter (VMAT), most probably at the amine
recognition site. The actions of reserpine on sympathetic neuronal
biochemical integrity have been well documented, and in the rat heart
include an increase the overflow of DHPG while decreasing the tissue
content of NE (Du et al., 1995
). The resultant increase in DHPG
overflow is readily explained by the known mechanism of action for
reserpine, and results from increased metabolism of intraneuronal NE by
monoamine oxidase, yielding DHPG.
Thus, given physiological data suggesting that amiodarone exerts antiadrenergic actions, and neurochemical data indicating a possible reserpine-like action, the aim of the current study was to investigate the effect of amiodarone on vesicular monoamine transport. To examine this question as directly as possible, we studied the action of amiodarone on monoamine transport in Chinese hamster ovary (CHO) cells transfected with cDNA encoding type 2 VMAT (VMAT2). Subsequently, binding experiments were performed to ascertain whether amiodarone binds to the amine recognition site.
| |
Materials and Methods |
|---|
|
|
|---|
Cell Culture and Transfection. CHO cells grown in 10% fetal calf serum to 60 to 70% confluency in 24-well plates (Falcon Labware, Oxnard, CA) were transiently transfected (Lipofectamine, Gibco-Life Technologies, Gaithersburg, MD) with an expression vector (pcDNA3) containing full-length cDNA for the bovine VMAT2 (kindly provided by Dr. B Gasnier, Institute de Biologie Physico-Chimique, Paris, France).
Monoamine Transport Assays.
Measurement of transport of
monoamines was performed as previously described (Steiner-Murdoch et
al., 1996
), In brief, 36 h after transfection, CHO cells were
washed with uptake buffer containing 110 mM potassium tartrate, 5 mM
glucose, 0.2% bovine serum albumin, 5 mM MgCl2, 1 mM
ascorbic acid, 10 µM pargyline, and 20 mM K-HEPES, pH 7.8. The
cells were permeabilized for 10 min at 37°C in uptake buffer
containing 10 µM digitonin. The medium was then replaced with fresh
buffer in the absence of digitonin containing 5 mM Mg-ATP and the
corresponding radiotracer (50 nM [3H]NE or 85 nM
[3H]dopamine) and drugs for the specific experiments and
incubated for 45 min at 37°C. At the end of the experiment the uptake
buffer was aspirated and cells washed with 1 ml of ice-cold uptake
buffer containing 5 mM MgSO4 with no tracer or drug added.
Cells were lysed with 0.1% Triton, and radioactivity subsequently
assessed by liquid scintillation counting. All experiments were
repeated at least three times.
[3H]Reserpine Binding.
[3H]reserpine binding was performed in lysates prepared
from transfected and untransfected CHO cells. Cells were collected by a
rubber policeman and suspended in a lysis buffer containing 0.15 M
NaCl, 10 mM K-HEPES, pH 8.5, 5 mM Na EGTA, and 1 µg/ml leupeptin, as
previously described (Steiner-Murdoch et al., 1996
). The cell lysate
suspension was then sonicated for 10 s using a Sonifer B-30 Cell
Disruptor (Branson Ultrasonics Corp., Danbury, CT). After
centrifugation (3500g, 5 min), cell debris was
discarded. The lysate then underwent ultracentrifugation
(50,000g, 60 min) in a Beckman TLX ultracentrifuge
(Beckman Instruments, Fuller, CA), and the supernatant discarded. The
remaining pellet was resuspended at a final concentration of 0.25 mg
protein/ml in binding buffer containing 320 mM sucrose, 10 mM K-HEPES,
pH 8.5, 4 mM KCl, 5 mM ATP, and 5 mM MgSO4 and stored at
80°C until use.
Intracellular pH (pHi) Recording.
To establish
the effect of amiodarone on pHi, CHO cells were also plated
on glass coverslips for fluorescence spectroscopy. Following
transfection with an expression vector containing VMAT2 cDNA (as
described above), studies of pHi were performed with the
pH-sensitive fluorescent indicator 2',7'-bis
(carboxyethyl)-5,6-carboxyfluorescein (BCECF; Molecular Probes, Eugene,
OR) (Weissberg et al., 1987
). Cells were loaded in buffer containing:
135 mM NaCl, 5 mM KCl, 1.8 mM CaCl2, 0.8 mM
MgSO4, 10 mM HEPES, 5.5 mM glucose, and 5 µM BCECF/AM, pH
7.4, for 30 min at 37°C, followed by washing in buffer solution for a
further 10 min at room temperature. Coverslips containing CHO cells
loaded with BCECF were subsequently loaded into a cuvette containing
the above buffer at pH 7.8 and 37°C, and positioned in a SPEX CM2
dual excitation spectrofluorimeter (SPEX Industries, Edison, NJ). Cells
were alternately excited at 440 nm and 495 nm, and the emitted
fluorescence was monitored at 530 nm.
Materials. Amiodarone, reserpine, and desethylamiodarone (DEA) were purchased from Sigma Chemical Co. (St. Louis, MO). [3H]NE and [3H]dopamine was obtained from New England Nuclear (Boston, MA). [3H]Reserpine was the kind gift of Professor Schuldiner (Hebrew University, Jerusalem, Israel). Solvent (DMSO) final dilutions were maintained at 1:10,000. A Bio-Rad DC protein assay kit (Bio-Rad, Hercules, CA) was used for protein determination.
Statistical Methods. Results are expressed as mean ± S.E.M. Between-group differences were tested using an unpaired t test. Analysis of variance was used for multiple comparisons and post hoc analysis was according to the method of Bonferroni. A value of <.05 was considered statistically significant. EC50 values were obtained by curve fitting using commercial software (Prism; GraphPad Software, San Diego, CA).
| |
Results |
|---|
|
|
|---|
Effect of Amiodarone and DEA on Monoamine Transport. CHO cells transfected with an expression vector containing full-length cDNA for VMAT2 robustly accumulated both [3H]NE and [3H]dopamine in comparison with untransfected cells (data not shown). Amiodarone inhibited VMAT2-mediated NE transport in a concentration-dependent manner, with an EC50 of 346 nM (Fig. 1A). At a concentration of 10 µM, amiodarone and its metabolite DEA potently inhibited VMAT2-mediated transport of dopamine and NE, reaching a similar degree of transport inhibition as that elicited by reserpine (Fig. 1B). Furthermore, amiodarone at a concentration of 10 µM also significantly inhibited the VAMT2-mediated transport of [3H]dopamine, with similar efficacy to that exhibited by 10 µM reserpine (Fig. 1C).
|
Effect of Amiodarone on [3H]Reserpine Binding. In an attempt to characterize the site at which amiodarone and DEA inhibit vesicular monoamine transport, we examined the influence of these compounds on the binding of [3H]reserpine to plasma membrane fractions purified from VMAT2-transfected CHO cells. Following incubation with [3H]reserpine, the radioactivity of membrane fractions obtained from control transfected CHO cells was 24084 ± 2510 dpm/µg. As depicted in Fig. 2, amiodarone competed for membrane binding with [3H]reserpine in a concentration-dependent fashion, with an EC50 of 173 nM, similar to that seen for the inhibitory action of amiodarone on VMAT2-mediated NE transport. In further experiments we also demonstrated that DEA also displaced reserpine from VMAT2-transfected plasma membranes, with a magnitude of effect similar to that of amiodarone (Fig. 2).
|
Influence of Amiodarone on pH.
To investigate the potential
role of a pH-mediated action of amiodarone on monoamine transport and
reserpine binding, we investigated the effect of amiodarone on
pHi in VMAT2-transfected CHO cells using a pH-sensitive
fluorescent indicator, BCECF. Amiodarone was completely without action
on pHi (Fig. 3), whereas
interventions that yield changes in pHi of approximately
±0.5 pH units could be readily detected (Borzak et al., 1990
;
Karwatowska-Prokopczuk et al., 1998
).
|
| |
Discussion |
|---|
|
|
|---|
Amiodarone is a complex drug with many pharmacological properties.
Aside from its actions on multiple ion channels, amiodarone also
exhibits a sympatholytic effect, which has been described as resulting
from both presynaptic and postsynaptic effects (Singh et al., 1989
).
Indeed, it has been suggested that the most crucial pharmacological
components of this clinically important antiarrhythmic agent are
related specifically to actions on the sympathetic nervous system.
Accordingly, the current study was designed to specifically examine the
action of amiodarone and its direct metabolite DEA on the vesicular
transport of monoamines.
To address this question as directly as possible, we examined the effect of amiodarone and DEA on monoamine uptake in CHO cells expressing VMAT2, and in conjunction, we examined the effect of these drugs on reserpine binding to VMAT2. The novel findings of this study are that both amiodarone and DEA appear to bind to VMAT2 at the amine recognition site and exhibit an inhibitory effect on the transport of monoamines. In complimentary experiments we showed that the inhibitory influence of amiodarone on VMAT2-mediated NE transport and [3H]reserpine binding were similar in magnitude to the actions of reserpine itself and occurred at an EC50 of 346 nM and 173 nM, respectively.
To date several VMATs have been cloned and sequenced (Schuldiner et
al., 1995
). Rat VMAT was initially cloned from rat brain (Erickson et
al., 1992
; Liu et al., 1992
), and subsequently two distinct VMATs
(VMAT1 and VMAT2) have been identified in the adrenal medulla and
brain, respectively. In this study we examined the effect of amiodarone
on VMAT2 activity because of indirect evidence suggesting an effect on
the vesicular storage of NE in the rat heart. Although a number of
compounds have been shown to inhibit the VMATs, reserpine and
tetrabenazine continue to be the best characterized. Reserpine appears
to bind directly to the amine recognition site (Darchen et al., 1989
)
and it has also been proposed that the binding site for reserpine is
located on the external aspect of the vesicular membrane (Chaplin et
al., 1985
). In contrast, tetrabenazine does not appear to act at the
amine recognition site, and its binding is not displaced by reserpine
(Henry and Scherman, 1989
). Together these data further support our
hypothesis that amiodarone attenuates vesicular monoamine transport by
binding to the reserpine binding site. The vesicular transport of
monoamines can be also be modified by compounds that alter the
vesicular transmembrane electrochemical gradient. Using fluorescence
spectroscopy, we were unable to detect any influence of amiodarone on
pHi in the same cellular model (transfected CHO
cells) as that used for investigating the action of amiodarone on
monoamine transport.
Given the wide range of substrates and inhibitors of the VMATs, it has
been postulated that binding site plasticity results from the
recognition of a small number of key elements within the substrate
(Schuldiner et al., 1995
). The key elements common to the inhibitors of
VMAT are an aromatic ring and a positive charge, and furthermore
hydroxyl, methoxy, or amino substituents in the ring improve affinity
for the substrates. Consistent with this hypothesis, amiodarone has a
diethylamino group located on an aromatic ring. Furthermore, a current
model for monoamine transport by the VMATs presumes a conformational
change of the protein following translocation of a
H+, which then exposes the amine binding site to
a monoamine or reserpine. It is then proposed that the long skeleton of
reserpine prevents a second conformational, which, under normal
circumstances, is responsible for monoamine translocation. Similarly,
amiodarone is also a molecule with a large skeleton, consistent with
our observation that amiodarone inhibits VMAT. In our study we also demonstrated that DEA, the principal metabolite of amiodarone, exerts
the same inhibitory effect on monoamine transport and reserpine binding.
Recent studies have clearly implicated the sympathetic nervous system
in the pathophysiology of arrhythmias and heart failure (Schwartz et
al., 1984
; Kaye et al., 1995
). The recognition of the mechanisms of
action of clinically important drugs, such as amiodarone, should
therefore provide a further impetus to the search for other more potent
agents with similar targets of action.
| |
Footnotes |
|---|
Accepted for publication September 15, 1998.
Received for publication May 12, 1998.
1 This work was supported by a block grant to the Baker Medical Research Institute from the National Health and Medical Research Council (Australia). D. H. was supported by Postgraduate Scholarships from the Baker Medical Research Institute and Alfred Healthcare Group. D. M. K. is the recipient of a Wellcome Trust Senior Research Fellowship.
Send reprint requests to: David M. Kaye, Molecular Neurocardiology Laboratory, Baker Medical Research Institute, Commercial Rd., Prahran, Victoria 3181 Australia. E-mail: david.kaye{at}baker.edu.au
| |
Abbreviations |
|---|
CHO, Chinese hamster ovary; VMAT2, type 2 vesicular monoamine transporter; BCECF, 2',7'-bis (carboxyethyl)-5,6-carboxyfluorescein; DHPG, dihydroxyphenylglycol; NE, norepinephrine; pHi, intracellular pH.
| |
References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
J. N. Nanas, E. P. Tsagalou, J. Kanakakis, S. N. Nanas, J. V. Terrovitis, T. Moon, and M. I. Anastasiou-Nana Long-term Intermittent Dobutamine Infusion, Combined With Oral Amiodarone for End-Stage Heart Failure: A Randomized Double-Blind Study Chest, April 1, 2004; 125(4): 1198 - 1204. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. V. DiGregorio Pharmacotherapeutic Advances in Cardiac Resuscitation: A Review of the Advanced Cardiac Life Support (ACLS) 2000 Guidelines and Their Impact on Pharmacy Practice Journal of Pharmacy Practice, February 1, 2001; 14(1): 41 - 53. [Abstract] [PDF] |
||||
![]() |
P S Macdonald, A M Keogh, C Aboyoun, M Lund, R Amor, and D McCaffrey Impact of concurrent amiodarone treatment on the tolerability and efficacy of carvedilol in patients with chronic heart failure Heart, November 1, 1999; 82(5): 589 - 593. [Abstract] [Full Text] |
||||
![]() |
D. M. Kaye, A. M. Dart, G. L. Jennings, and M. D. Esler Antiadrenergic effect of chronic amiodarone therapy in human heart failure J. Am. Coll. Cardiol., May 1, 1999; 33(6): 1553 - 1559. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||